Although the ideas put forth by Goldschmidt-Clermont et al 1 are intriguing, we believe that their article underplays a large body of work, much of it from the past 2 decades, that has clarified how normal arteries become atherosclerotic. [2] [3] [4] [5] Low-density lipoprotein (LDL) is not mysteriously injurious. Instead, as experimentally demonstrated by Skålén et al, 4 LDL causes harm only if it becomes retained, or trapped, within the arterial wall. Moreover, without LDL retention, atherosclerosis does not develop, even if other known risk factors are present. There are no known circumstances in humans or in animal models in which atherosclerosis is caused by stem cell defects, inflammation, senescence, or endothelial injury per se in the absence of unhealthy levels of LDL or related particles in plasma (meaning above a therapeutically attainable goal of ‫07ف‬ mg/dL). 2 Retained LDL provokes a series of responses in the arterial wall that accounts for all known features of this disease, including the development of the lipid-rich vulnerable plaque. The therapeutic implications of these hard-won insights are clear: We should lower unhealthy plasma levels of LDL and modify other conventional risk factors, and we should enhance "reverse" lipid transport out of plaques. Benefits from these approaches have been demonstrated in animal models and in humans. 5 In contrast, clinical trials of antioxidants, antiinflammatory agents, and antibacterials have shown no benefits in this disease to date, 5 and the potential utility of stem cells remains highly speculative. We agree with Goldschmidt-Clermont et al 1 that there is a need for further study and therapeutic improvements, 5 but it is important to emphasize that our field already has robust, proven remedies that are based on a well-tested understanding of the pathogenesis of this major killer.
